Enhancing healthy lifespan

Apollo Health Ventures develops interventions with the potential to prevent or reverse age-related diseases and extend healthy human lifespan.

Apollo Health Ventures is currently investing out of its Fund II with a fund size of EUR 157.5 million.

The biology of aging

Our interventions target the underlying causes of age-related damage and dysfunction at the molecular, cellular and tissue level.
Apollo's investment approach is indication agnostic. However, Apollo only invests in therapeutics that affect one of the major root causes of aging.
Click THE CIRCLES
to learn more
Impaired metabolic homeostasis
Mitochondrial dysfunction
Inadequate stress response
Stem cell exhaustion
Disrupted tissue homeostasis
Altered intercellular signaling
Genome instability
Epigenetic modifications
Deregulated macromolecular homeostasis
Our Values
Chart
For the first time in history the diseases that come as a consequence of old age–such as cancer, heart attacks, stroke, and dementia–outweigh infectious disease as humankind's largest killers.

Healthcare spendings for the population with an age of over 65 exceed 2 trillion USD in the US and Europe. The risk of getting any age-related disease increases exponentially around and after the age of 65. The risk for these kinds of diseases increases simultaneously, leading to the occurrence of multiple diseases of aging per individual, also referred to as multimorbidity.

Thus, Apollo is not targeting single diseases but the root causes of aging to increase health span and the quality of life.
Chart
New insights into the basic biology of aging, the underlying cause of all of these conditions, are enabling the creation of new therapies to prevent and even reverse these agonising diseases, allowing people to live healthier and more productive lives.
Chart
The life-science industry is on the verge of an inflection point since new technologies like machine learning, lab automation and gene editing technologies enabling innovative biotechs to pursue bigger opportunities than ever before.
Diagram
Apollo collaborates with scientists and entrepreneurs to combine the most innovative findings of ageing research with state of the art catalysing technologies.

Furthermore, Apollo supports its portfolio companies with strategic advice, hiring, data driven indication selection, drug development plans, IP strategy, pharma collaborations and finding syndication partners in further fundraising rounds.

Venture development

Apollo Health Ventures works with leading scientists and entrepreneurs to translate scientific discoveries into high-impact medicines.

01

Evaluate

Survey the full scope of aging research to identify potential longevity technologies

MOLECULAR ALTERATIONS

Reverse the changes and damage to the genome and macromolecules

CELLULAR DYSFUNCTION

Restore homeostasis in metabolic activity and stress response

TISSUE DEGENERATION

Regenerate tissues by altering the cellular and extracellular environment

02

Incubate

Validate the viability of a project and create the foundation for new biotech ventures

EXPERTISE

Establish collaborations with experts and key opinion leaders

INTELLECTUAL PROPERTY

Identify, secure and protect IP and know-how

PROOF OF CONCEPT

Design “killer experiment” to derisk project

R&D STRATEGY

Define research and development plan and budget

03

Accelerate

Execute strategy for time and cost efficient development of novel therapeutics

TALENT & TEAM

Leadership team with deep expertise in biotech, scientific and medical talent and advisors

LEAN OPERATIONS

Lean and flexible drug development to maximize capital efficiency of start-ups

CLINICAL STRATEGY

Clinical development for existing indications of high unmet medical need with clear regulatory paths

Insights

Learn more about recent advances in longevity, biotechnology and our work.

VIEW ALL

Get in touch

We are looking forward to hearing from you about opportunities to collaborate and share more information about our work.